COMMUNIQUÉS West-GlobeNewswire

Oxford Immunotec Reports Third Quarter 2018 Financial Results

09/11/2018 - 13:15

Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT ® .TB tests sold in the third quarter exceeded one million tests for the first time Significant improvement in GAAP net [...]

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection

09/11/2018 - 13:00

- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently [...]

Neos Therapeutics Reports Third Quarter 2018 Financial Results

09/11/2018 - 13:00

Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical company focused on developing [...]

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

09/11/2018 - 13:00

--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology-- ZUG, Switzerland and CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. [...]

VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update

09/11/2018 - 13:00

-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of VBI-1901 for the treatment of [...]

Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting

09/11/2018 - 13:00

XYOSTED™ AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION EWING, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from the 26-week Phase 3 [...]

Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update

09/11/2018 - 13:00

Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3 interim analysis [...]

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress

09/11/2018 - 13:00

LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat [...]

PLx Pharma Inc. Reports Third Quarter 2018 Results

09/11/2018 - 12:50

PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company [...]

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018

09/11/2018 - 12:00

RANCHO CUCAMONGA, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Jefferies London [...]

Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions

09/11/2018 - 12:00

NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal [...]

RadNet Reports Third Quarter Financial Results and Reaffirms Previously Announced 2018 Guidance Levels

09/11/2018 - 12:00

Total Net Revenue (“Revenue”) increased 6.4% to $242.1 million in the third quarter of 2018 from $227.6 million in the third quarter of 2017 Adjusted EBITDA (1) increased 5.5% to $38.1 million in the third quarter of [...]

NASH clinical trial presentation and continued revenue growth

09/11/2018 - 12:00

Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San Francisco Travelan® on display at HealthEd Australian Travelan® sales continue to grow, with a Q1 CY19 [...]

AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases

09/11/2018 - 10:01

Increasing evidence points to Abeta oligomers as the toxic species in AD, and likely linked to Tau pathology and neuroinflammation. Immunotherapies and small molecule anti-Tau therapeutics hold much promise in treating [...]

Rule 2.9 Announcement

09/11/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 9 November 2018 [...]

Bavarian Nordic Announces Interim Results for the First Nine Months of 2018

09/11/2018 - 07:49

COPENHAGEN, Denmark, November 9, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results in line with guidance for the first nine months of 2018 and business progress for the [...]

Nine-month interim report (Q3) 2018

09/11/2018 - 07:33

Better than expected performance continued in Q3 (unaudited) Financial results in Q3 were again better than expected and the full-year outlook has been updated accordingly. Execution of ALK’s growth strategy saw good [...]

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

09/11/2018 - 07:32

Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting Three abstracts on Viaskin [...]

DBV Technologies présentera des données soutenant l'utilisation de l'immunothérapie épicutanée pour le traitement de l'allergie à l'arachide à l'ACAAI 2018

09/11/2018 - 07:32

Montrouge, France, le 9 novembre (07h30 CEST), 2018 DBV Technologies présentera des données soutenant l'utilisation de l'immunothérapie épicutanée pour le traitement de l'allergie à l'arachide à l'ACAAI 2018 Trois [...]